ZAZNĚLO NA XXXVII. sjezdu českých a slovenských alergologů a klinických imunologů – On-line: 8.–9. 10. 2020

37 www.solen.cz SOLEN ZAZNĚLO NA XXXVII. SJEZDU ČESKÝCH A SLOVENSKÝCH ALERGOLOGŮ A KLINICKÝCH IMUNOLOGŮ LABA. Tento inhalátor využívá inovativní techno- logii chlopně a zalomené hadičky. Zajišťuje plicní biologickou dostupnost flutikazon propionátu a formoterolu srovnatelnou s použitím flutifor- mu® pMDI. Kolem 40 % vytvořených částic je <5 µm, díky čemuž se léčivé látky dostávají do malých i velkých dýchacích cest. Většina paci- entů považuje používání inhalátoru flutiform k‑haler® za jednodušší a dala by mu přednost před svým stávajícím inhalátorem. Flutiform® k‑haler® se dodává s názornými pokyny k použití na obalu s cílem dlouhodobě u pacientů udržet správnou inhalační techniku. Připravila MUDr. Zuzana Zafarová LITERATURA 1. Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chry- styn H. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med. 2010 Sep; 104(9): 1237–1245. 2. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In‑Check Dial to identify these rates. Re- spir Med. 2003 Feb; 97(2): 181–187. 3. Giraud V, Allaert FA, Roche N. Inhaler technique and ast- hma: feasability and acceptability of training by pharmacis- ts. Respir Med. 2011 Dec; 105(12): 1815–1822. 4. Westerik JA, Carter V, Chrystyn H, Burden A, Thompson SL, Ryan D, Gruffydd‑Jones K, Haughney J, Roche N, Lavorini F, Papi A, Infantino A, Roman‑Rodriguez M, Bosnic‑Anticevich S, Lisspers K, Ställberg B, Henrichsen SH, van der Molen T, Hutton C, Price DB. Characteristics of patients making se- rious inhaler errors with a dry powder inhaler and associa- tion with asthma‑related events in a primary care setting. J Asthma. 2016; 53(3): 321–329. 5. GINA. Global strategy for asthma management and preven- tion. 2017. dostupné na: https://ginasthma.org/wp‑content/ uploads/2019/04/wmsGINA-2017-main‑report‑final_V2.pdf 6. Price DB, Román‑Rodríguez M, McQueen RB, Bosnic­ ‑Anticevich S, Carter V, Gruffydd‑Jones K, Haughney J, Hen- richsen S, Hutton C, Infantino A, Lavorini F, Law LM, Lisspers K, Papi A, Ryan D, Ställberg B, van der Molen T, Chrystyn H. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. J Allergy Clin Immunol Pract. 2017 Jul‑Aug; 5(4): 1071–1081.e9. 7. Price DB, Pearce L, Powell SR, Shirley J, Sayers MK. Handling and acceptability of the Easi‑Breathe device compared with a conventional metered dose inhaler by patients and practice nurses. Int J Clin Pract. 1999 Jan–Feb;53(1):31–6. 8. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inha- lation devices. EDICI. Respir Med. 2000 May; 94(5): 496–500. 9. SPC flutiform k‑haler. www.sukl.cz 10. Bell D, Mundin G, Lomax M, Woodward J, Dissanayake S, Overend T. Relative pulmonary bioavailability (BA) of flu- ticasone propionate/formoterol (FP/FORM) via pressurised metered‑dose inhaler (pMDI) and a novel breath‑triggered inhaler (BTI). European Respiratory Journal 2017 50: PA523; 11. Bell D, Mansfield L, Loma, M.A. Randomized, Crosso- ver Trial Evaluating Patient Handling, Preference, and Ease of Use of the Fluticasone Propionate/Formoterol Breath­ ‑Triggered Inhaler. J Aerosol Med Pulm Drug Deliv. 2017 Dec; 30(6): 425–434. 12. Kappeler D, Sommerer K, Kietzig C, Huber B, Woodward J, Lomax M, Dalvi P. Pulmonary deposition of fluticasone pro- pionate/formoterol in healthy volunteers, asthmatics and COPD patients with a novel breath‑triggered inhaler. Respir Med. 2018 May; 138: 107–114. 13. Tuohy J, Marshall J, Danagher H. Plume spray force of three HFA‑propelled ICS/LABA combination inhalers. European Re- spiratory Journal 2017 50: PA524. 14. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Bro- eders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK. Effect of incorrect use of dry pow- der inhalers on management of patients with asthma and COPD. Respir Med. 2008 Apr; 102(4): 593–604. 15. Vinker S, Eliyahu V, Yaphe J. The effect of drug informa- tion leaflets on patient behavior. Isr Med Assoc J. 2007 May; 9(5): 383–386. 16. Basheti IA, Obeidat NM, Reddel HK. Effect of novel inhaler technique reminder labels on the retention of inhaler tech- nique skills in asthma: a single‑blind randomized controlled trial. NPJ Prim Care Respir Med. 2017 Feb 9; 27(1): 9.